Quarterly ResultAug 5, 2026, 04:14 PM
Biodesix Q2 Revenue $26.86M, Net Loss Narrows; Equity Turns Positive
AI Summary
Biodesix reported increased revenues and a narrowed net loss for both the second quarter and first half of 2026. Q2 2026 revenues rose to $26.86 million, with net loss improving to $7.27 million. For the six months ended June 30, 2026, revenues reached $52.42 million, and net loss was $15.07 million. The company's cash position significantly improved, and total stockholders' equity turned positive to $9.14 million, primarily driven by $23.89 million in proceeds from common stock issuance.
Key Highlights
- Q2 2026 revenues increased to $26.86 million from $20.02 million in Q2 2025.
- Q2 2026 net loss narrowed to $7.27 million from $11.47 million in Q2 2025.
- Six-month 2026 revenues grew to $52.42 million from $37.98 million in 2025.
- Six-month 2026 net loss improved to $15.07 million from $22.57 million in 2025.
- Cash and cash equivalents rose to $29.99 million as of June 30, 2026, from $18.99 million at year-end 2025.
- Total stockholders' equity turned positive to $9.14 million from a $2.47 million deficit at year-end 2025.
- Received $23.89 million from common stock issuance in the first half of 2026.
- Net cash used in operating activities improved to $11.73 million from $15.17 million in the prior year period.
- A 1-for-20 reverse stock split was effective September 15, 2025.
Price Impact
More from BDSX